Experienced in Peripheral T-Cell Lymphoma

Kirill V. Lepik

Saint Petersburg, SPE, RU 
Experienced in Peripheral T-Cell Lymphoma
Saint Petersburg, SPE, RU 
OverviewLocationsClinical Research

Overview

Kirill Lepik practices in Saint Petersburg, Russian Federation. Mr. Lepik is rated as an Experienced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Saint Petersburg, SPE, Russian Federation

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple Myeloma
Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2024
Intervention Type: Procedure, Drug
Study Drugs: Melphalan, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab Combination (BeGeRN) in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab Combination (BeGeRN) in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Enrollment Status: Completed
Publish Date: June 07, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed or Refractory Hodgkins Lymphoma.
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed or Refractory Hodgkins Lymphoma.
Enrollment Status: Completed
Publish Date: January 23, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

33 Total Publications

Five-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy.
Five-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy.
Journal: Hematological oncology
Published: May 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lepik's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile